Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1917-1923

  Jeha, Sima ^a   Gaynon, Paul S ^b   Razzouk, Bassem I ^b   Franklin, Janet ^b   Kadota, Richard ^b   Shen, Violet ^b   Luchtman Jones, Lori ^b   Rytting, Michael ^b   Bomgaars, Lisa R ^b   Rheingold, Susan ^b   Ritchey, Kim ^b   Albano, Edythe ^b   Arceci, Robert J ^b   Goldman, Stewart ^b   Griffin, Timothy ^b   Altman, Arnold ^b   Gordon, Bruce ^b   Steinherz, Laurel ^b   Weitman, Steven ^b   Steinherz, Peter ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; DEOXYADENOSINE DERIVATIVE; ADENINE NUCLEOTIDE; ARABINONUCLEOSIDE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BACTEREMIA; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEBRILE NEUTROPENIA; FEVER; HALLUCINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PETECHIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SEPSIS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; FEMALE; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; TREATMENT OUTCOME;

ADENINE NUCLEOTIDES; ADOLESCENT; ADULT; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; RECURRENCE; TREATMENT OUTCOME;

EID: 33646337195     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8554     Document Type: Article

References (34)

1. Pui CH: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
2. Kersey JH: Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90: 4243-4251, 1997
3. Henze G, Fengler R, Hartmann R, et al: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): A relapse study of the BFM group. Blood 78:1166-1172, 1991
4. Sadowitz PD, Smith SD, Shuster J, et al: Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 81:602-609, 1993
5. Wheeler K, Chessells JM, Bailey CC, et al: Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child 74:101-107, 1996
6. Carlson L, Ho P, Smith M, et al: Pediatric phase I drug tolerance: A review and comparison of recent adult and pediatric phase I trials. J Pediatr Hematol Oncol 18:250-256, 1996
7. Hirschfeld S, Ho P, Smith M, et al: Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives. J Clin Oncol 21:1066-1073, 2003
8. Chan K: Acute lymphoblastic leukemia. Curr Probl Pediatr Adolesc Health Care 32:40-49, 2002
9. Chessells J, Veys P, Kempski H, et al: Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 123:396-405, 2003
10. Cheson B, Vena D, Foss F, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
11. Mansson E, Flordal E, Liliemark J, et al: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65:237-247, 2003
12. Yamauchi T, Nowak B, Keating M, et al: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589, 2001
13. Plunkett W, Gandhi V: Purine and pyrimidine nucleoside analogs, in Giacconi G, Schilsky R, Sondel P (eds): Cancer Chemotherapy and Biological Response Modifiers, Annual 19. Oxford, United Kingdom, Elsevier Science, 2001, pp 21-24
14. Parker W, Shaddix S, Rose L: Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabino-furanosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl) adenine in CEM cells. Mol Pharmacol 55:515-520, 1999
15. Waud W, Schmid S, Montgomery J, et al: Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (CI-F-ara-A). Nucleosides Nucleotides Nucleic Acids 19: 447-460, 2000
16. Carson D, Wasson D, Esparza L, et al: Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2-arabino-fluoro-2-deoxyadenosine. Proc Natl Acad Sci U S A 89:2970-2974, 1992
17. Jeha S, Gandhi V, Chan K, et al: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103:784-789, 2004
18. Kantarjian H, Gandhi V, Kozuch P, et al: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167-1173, 2003
19. Kantarjian H, Gandhi V, Cortes J, et al: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379-2386, 2003
20. Bonate P, Craig A, Gaynon P, et al: Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 44:1309-1322, 2004
21. Weitman S, Ochoa S, Sullivan J, et al: Pediatric phase II cancer chemotherapy trials: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 19:187-191, 1997
22. Harris R, Sather H, Feig S: High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: The Children's Cancer Group experience. Med Pediatr Oncol 30:233-239, 1998
23. McCarthy A, Pitcher L, Hann I, et al: FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol 32:411-415, 1999
24. Kolb E, Steinherz P: A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 17:1967-1972, 2003
25. Holland J, Frei E, Bast RC, et al: Cancer Medicine (ed 4). Baltimore, MD, Williams & Wilkins, 1973
26. Santana V, Mirro J, Harwood F, et al: A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9:416-422, 1991
27. Berg S, Blaney S, Devidas M, et al: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J Clin Oncol 23:3376-3382, 2005
28. Pulkkanen K, Kataja V, Johansson R: Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: A case report. J Chemother 15:287-289, 2003
29. Pavlakis N, Bell D, Millward M, et al: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80:286-291, 1997
30. De Pas T, Curigliano G, Franceschelli L, et al: Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 12:1651-1652, 2001
31. Winkler U, Jensen M, Manzke O, et al: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217-2224, 1999
32. Ek T, Jarfelt M, Mellander L, et al: Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol 37:459-464, 2001
33. Ek T, Abrahamsson J: The paediatric cytarabine syndrome can be viewed as a drug-induced cytokine release syndrome. Br J Haematol 124:691, 2004
34. Hijiya N, Metzger M, Pounds S, et al: Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer 43:1-7, 2004